Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant PK with Carbamazepine Interaction
NCT05028608Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elinzanetant in vasomotor symptoms, sponsored by Bayer. Primary endpoints: Area Under the Curve of Elinzanetant with Carbamazepine, Area Under the Curve of Elinzanetant without Carbamazepine and 2 more. Started Sep 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT05028608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028608.